RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

As the double expresso finally exerts an effect: The other possibility is that, if the compound shows well in a EU Phase I, Cortex could then assess whether they think it is better than whatever Les Street et al has devised here, and it would have the advantage of having shown it in humans. If so, they could then file an IND in the US with the Servier Phase I data, and could initiate a Phase IIa in Alzheimer's. That decision-point could be in 12-18 months.

But I'm a lot more focused on the next--days? weeks?--than I am in possibilities for 2012.

NeuroInvestment